{
  "id": "526c190d-fb42-45c3-9f9a-eb6e9a06eed1",
  "title": "Doen√ßa de Kawasaki",
  "author": "Dra. Dania",
  "category": "Reumatologia",
  "htmlContent": "<!DOCTYPE html>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" lang xml:lang>\n<head>\n  <meta charset=\"utf-8\" />\n  <meta name=\"generator\" content=\"pandoc\" />\n  <meta name=\"viewport\" content=\"width=device-width, initial-scale=1.0, user-scalable=yes\" />\n  <title>DOEN√áA DE KAWASAKI ROTINAS HRT DANIA</title>\n  <style>\nhtml {\ncolor: #1a1a1a;\nbackground-color: #fdfdfd;\n}\nbody {\nmargin: 0 auto;\nmax-width: 36em;\npadding-left: 50px;\npadding-right: 50px;\npadding-top: 50px;\npadding-bottom: 50px;\nhyphens: auto;\noverflow-wrap: break-word;\ntext-rendering: optimizeLegibility;\nfont-kerning: normal;\n}\n@media (max-width: 600px) {\nbody {\nfont-size: 0.9em;\npadding: 12px;\n}\nh1 {\nfont-size: 1.8em;\n}\n}\n@media print {\nhtml {\nbackground-color: white;\n}\nbody {\nbackground-color: transparent;\ncolor: black;\nfont-size: 12pt;\n}\np, h2, h3 {\norphans: 3;\nwidows: 3;\n}\nh2, h3, h4 {\npage-break-after: avoid;\n}\n}\np {\nmargin: 1em 0;\n}\na {\ncolor: #1a1a1a;\n}\na:visited {\ncolor: #1a1a1a;\n}\nimg {\nmax-width: 100%;\n}\nsvg {\nheight: auto;\nmax-width: 100%;\n}\nh1, h2, h3, h4, h5, h6 {\nmargin-top: 1.4em;\n}\nh5, h6 {\nfont-size: 1em;\nfont-style: italic;\n}\nh6 {\nfont-weight: normal;\n}\nol, ul {\npadding-left: 1.7em;\nmargin-top: 1em;\n}\nli > ol, li > ul {\nmargin-top: 0;\n}\nblockquote {\nmargin: 1em 0 1em 1.7em;\npadding-left: 1em;\nborder-left: 2px solid #e6e6e6;\ncolor: #606060;\n}\ncode {\nfont-family: Menlo, Monaco, Consolas, 'Lucida Console', monospace;\nfont-size: 85%;\nmargin: 0;\nhyphens: manual;\n}\npre {\nmargin: 1em 0;\noverflow: auto;\n}\npre code {\npadding: 0;\noverflow: visible;\noverflow-wrap: normal;\n}\n.sourceCode {\nbackground-color: transparent;\noverflow: visible;\n}\nhr {\nbackground-color: #1a1a1a;\nborder: none;\nheight: 1px;\nmargin: 1em 0;\n}\ntable {\nmargin: 1em 0;\nborder-collapse: collapse;\nwidth: 100%;\noverflow-x: auto;\ndisplay: block;\nfont-variant-numeric: lining-nums tabular-nums;\n}\ntable caption {\nmargin-bottom: 0.75em;\n}\ntbody {\nmargin-top: 0.5em;\nborder-top: 1px solid #1a1a1a;\nborder-bottom: 1px solid #1a1a1a;\n}\nth {\nborder-top: 1px solid #1a1a1a;\npadding: 0.25em 0.5em 0.25em 0.5em;\n}\ntd {\npadding: 0.125em 0.5em 0.25em 0.5em;\n}\nheader {\nmargin-bottom: 4em;\ntext-align: center;\n}\n#TOC li {\nlist-style: none;\n}\n#TOC ul {\npadding-left: 1.3em;\n}\n#TOC > ul {\npadding-left: 0;\n}\n#TOC a:not(:hover) {\ntext-decoration: none;\n}\ncode{white-space: pre-wrap;}\nspan.smallcaps{font-variant: small-caps;}\ndiv.columns{display: flex; gap: min(4vw, 1.5em);}\ndiv.column{flex: auto; overflow-x: auto;}\ndiv.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}\n\nul.task-list[class]{list-style: none;}\nul.task-list li input[type=\"checkbox\"] {\nfont-size: inherit;\nwidth: 0.8em;\nmargin: 0 0.8em 0.2em -1.6em;\nvertical-align: middle;\n}\n.display.math{display: block; text-align: center; margin: 0.5rem auto;}\n</style>\n</head>\n<body>\n<p>DOEN√áA DE KAWASAKI - DK</p>\n<ul>\n<li><p><strong>Aspectos Gerais:</strong></p></li>\n</ul>\n<p>Ou S√≠ndrome Mucocut√¢nea Ganglionar, √© uma vasculite de m√©dios vasos,\naguda, difusa, de etiologia desconhecida, autolimitada e, na maioria das\nvezes, benigna. Predomina em crian√ßas abaixo dos 5 anos (85%), com pico\nentre 1 e 2 anos, especialmente no sexo masculino (1,5 : 1) e em\ncrian√ßas japonesas em rela√ß√£o √†s caucasianas. Caracterizada por febre\nalta prolongada, inflama√ß√£o difusa de mucosas, altera√ß√µes de pele e\nlinfadenopatia cervical n√£o-supurativa. √â mais comum nos meses de\ninverno e primavera. Nos pa√≠ses desenvolvidos, em que a Febre Reum√°tica\nj√° foi controlada, √© a primeira causa de cardiopatia adquirida na\ninf√¢ncia.</p>\n<ul>\n<li><p><strong>Patologia:</strong></p></li>\n</ul>\n<p>As altera√ß√µes histol√≥gicas encontradas na DK consistem em vasculite\nsist√™mica generalizada, afetando predominantemente vasos de m√©dio\ncalibre com predile√ß√£o pelas art√©rias coron√°rias. Altera√ß√µes\ninflamat√≥rias sist√™micas podem ser observadas em v√°rios √≥rg√£os causando\nmiocardite, pericardite, vasculites, meningite ass√©ptica, pneumonite,\nlinfadenite e hepatite.</p>\n<ul>\n<li><p><strong>Crit√©rios Diagn√≥sticos:</strong></p></li>\n</ul>\n<p><strong>Crit√©rio mandat√≥rio:</strong></p>\n<ul>\n<li><p>Febre por cinco dias ou mais</p></li>\n</ul>\n<p><strong>Mais 4 dos seguintes crit√©rios:</strong></p>\n<p>Hiperemia conjuntival bilateral, n√£o purulenta (80 ‚Äì 90%);</p>\n<p>L√≠ngua em framboesa, eritema e edema de orofaringe, fissuras e\neritema labial (80 ‚Äì 90%);</p>\n<p>Eritema e edema de m√£os e p√©s (fase aguda) ou descama√ß√£o periungueal\n(na fase de convalescen√ßa) ‚Äì 80%;</p>\n<p>Exantema polim√≥rfico, especialmente no tronco, n√£o vesicular\n(&gt;90%);</p>\n<p>Linfonodomegalia cervical, com. Pelo menos, um linfonodo <u>&gt;</u>\n1,5cm (50%);</p>\n<p>Alguns pacientes (15 a 20%) s√£o diagnosticados como portadores de\n<strong>DK at√≠pica ou incompleta</strong> uma vez que n√£o preenchem\ntodos os crit√©rios diagn√≥sticos propostos. O termo mais apropriado e\n<strong>DK</strong> <strong>incompleta</strong>, pois esses pacientes\napresentam alguns dos sintomas t√≠picos da doen√ßa e n√£o manifesta√ß√µes\nat√≠picas. A DK incompleta deve ser considerada em todas as crian√ßas com\nfebre inexplicada por mais de cinco dias associada a 2 ou 3 dos\nprincipais achados cl√≠nicos da DK. A forma incompleta √© mais frequente\nem crian√ßas menores de 6 meses. O diagn√≥stico da DK incompleta √© baseado\nem achados ecocardiogr√°ficos de altera√ß√µes nas art√©rias coron√°rias;\nmesmo naqueles pacientes com menos de 3 crit√©rios diagn√≥sticos, por√©m\ncom les√£o coronariana, o tratamento √© indicado com imunoglobulina\nintravenosa. Os crit√©rios diagn√≥sticos convencionais propostos pela\nAmerican Heart Association s√£o falhos para reconhecer a forma incompleta\nda doenca.</p>\n<ul>\n<li><p><strong>Quadro Cl√≠nico:</strong></p></li>\n</ul>\n<p><strong>Febre:</strong></p>\n<p>√â um sinal caracter√≠stico da fase aguda da doen√ßa, √© geralmente alta\n(acima de 39¬™C-40¬™C), remitente e acompanhada de extrema irritabilidade.\nO primeiro dia de febre √© considerado o 1¬∫ dia de doen√ßa. A febre dura,\nem m√©dia, 1 a 2 semanas, podendo, na aus√™ncia de tratamento, estender-se\nat√© 3 ou 4 semanas. Responde parcialmente ao uso de antipir√©ticos, mas\nn√£o cessa com a introdu√ß√£o de antibi√≥ticos. Com o in√≠cio da\nimunoglobulina intravenosa (IGIV) e aspirina a febre cessa em 2\ndias.</p>\n<p><strong>Conjuntivite:</strong></p>\n<p>√â bilateral n√£o exsudativa e envolve principalmente a conjuntiva\nbulbar em rela√ß√£o √†s conjuntivas palpebral e tarsal, √© indolor e ocorre\nna fase aguda da doen√ßa.</p>\n<p><strong>Altera√ß√µes da mucosa oral:</strong></p>\n<p>S√£o caracterizadas por eritema difuso da orofaringe, l√°bios secos,\nfissurados, vermelhos e sangrantes e a l√≠ngua se apresenta com aspecto\nde ‚Äúframboesa‚Äù ou ‚Äúmorango‚Äù (eritema intenso com papilas gustativas\nproeminentes).</p>\n<p><strong>Altera√ß√µes de extremidades:</strong></p>\n<p>Na fase aguda da doen√ßa tamb√©m s√£o descritos o eritema e/ou indura√ß√£o\nde regi√µes palmar e plantar acompanhados de aumento da sensibilidade\ndolorosa; ap√≥s 2 ou 3 semanas de doen√ßa ‚Äì fase subaguda ‚Äì inicia-se a\ndescama√ß√£o periungueal dos p√©s e m√£os, que progride para palmas e\nplantas. Um ou dois meses ap√≥s instalado o quadro, podem surgir linhas\nde Beau (sulcos transversais) nas unhas afetadas.</p>\n<p><strong>Exantema:</strong></p>\n<p>√â de car√°ter variado, n√£o pruriginoso, polim√≥rfico (macular, papular,\neritrod√©rmico, escarlatiniforme), surge inicialmente no tronco,\ndistribui-se em membros e se torna confluente na regi√£o perineal,\ndurando, em m√©dia, 7 dias.</p>\n<p><strong>Linfadenodomegalia:</strong></p>\n<p>H√° aumento de g√¢nglios cervicais (<u>&gt;</u> 1,5cm), geralmente\nanteriores, uni ou bilaterais. Ap√≥s 3 ou 4 dias come√ßam a regredir. Os\nlinfonodos afetados s√£o indolores ou pouco dolorosos, n√£o flutuantes e\nn√£o supurativos; o eritema da pele suprajacente pode ocorrer.</p>\n<p><img src=\"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAy8AAAHTCAMAAAAZPNdJAAAAwFBMVEW15/cpKSkHQkz+zgKgKotmfIOWu8sI1axVZWx4l6U2RkmLrQvENTcBAgQ6Wl8YLDMDZH2cyNiTqbIzb4EYUmKq2OwSFyJOWAp3qLiAKP13K+uStUXt0SpB0LgjNh8ZrJB7L2YcMkU6SCnm2mImAg+6mbWfYJrcyCxo3tHY4J7/3hANYlRICQ+hxnQhAz2u051VG6Yhc4DCtM69dIA0YVnQ5cp2SNaOduC9471ghnG3zb+F+eoVLBjGryPFsFX44iz1+YWHAABF+klEQVRo3uyba2/buBKGpQQkSG2tgLKZ6kNw0DTtBi2yOEBPA6TFtv3//+rwriEpyYotO7Y1L3YbSaZ40zya4UVFgUKhUCgUCoVCoVAoFAqFQqFQKBQKhULtL068xP6Z0SslgZ2KuliRKy86T2YE+xSFvEx2LxT7FIW8oHtBoYpCUC+5v3+ZJRcUCg6urUVJM8Z211stcEjBRW7TtZ0oPDG30bV6s9etjMbvhGeZm4JblYS3ojvXaf35SM5dDlTd0tprHLRCmIxMlv52aesbfknuNiXoJP5M8o32UcHVCdsQWH6UPjS4FbCFwy3KurevS9Iui4tIuwj2Qmt7Pi6ge9St/xE8/aistP3w17SQFnTqhcrEPdaMW3MM4v4NiI/qcBT/sWqLK6CQ19XVWkbpSJa5fiDhV9F3PpJzsMaNu8hlqF1XUusPuqO2+yW5W2sdflO/rkMTQZa6/p1dwPQwoPTze+Mtyro3vyHtsrSIpItgXi2oPcik9tOGxD//NjyfqKz+9m/6C6FJR1wqL3X32F1/czB+IKG/JvNCISEZLzDzQtRXMJ9CbOLzsZxdDusuwYaO8bKROS/J3dpELI8DgylQAYdXlD66xzIFW7Rp+3mB3Zt1SdplWRHDvLQDmXCPSXj+JKSLysran1kGKGQpvJg3jQT97Y456LKNfAUv4CeR8RJlLiEeKp/4XD+XkZxtDnWcwwgv+jDhJb07WMSVoUGkrANe/BWYPrExXf9pLQLdm3ZJ2mV5EYO8RLjATITDRIS6b3wborKy9ueWAQq5fF5A81tghe64hs+G9/LiAlfzyDZulOI6v3WvLBXuWq/v4t6+zAnZ2K521sN57c1oJOfhHAZ4UdklvKR3+1jFnZi6rlsQg9h4BNphHQcsLk+bpJZbW9TfvXGVoi7Li4gz7BJEuMSZuIAsdg3rLFnW/vzhgUIunxfaNX8N3C6Br3B/Ivt4gX6KxF5LyjA71cJoAmZOu8imDW8oO5BogecazhnkINsoqunjRVllzEt2d/dKJaHi3E7ZwSxtFLfJ0mev3XZri9LuTbskex5ZEUmGqQNqe/rdB2Tc152HlFGyrP29lhENkJbAi7JlCcJUf2zdLgknk3kx1gTmsCAvUeY8edTwvLUkj+ec5TDOy5WMeeG5qYWxtgz3cZr0mI8b2zR9FtbXW1uUdm9PleLnkRUxzkvbm4kLyJxv3HQTAHGytP39luELWQ4vPMw7UTAHBaZtzE9D8ZgoQEgAYrswDQl5iTKv48g/Prcn4zlbgORkXkjMS3Z3CK/cg9/4YbVMsmy91dSpYYYamF+2tijt3jqvUvw8siKSDGNe2oFMzJ2hW7pZryRZ0v4By2iLhfDi278Jj51G7w0Bz8jQeD8acpJuri2Ov7MZF4fZOpl+WEdvejqec5bDFl5suB14ye4GI1wSDe/9/HWYKHBJRD5h52sQPM9oi9LuzauUPI+siHwKorulHcrE3Bk6s+7xGaKn/f2W0RZL4+WqBWZonW6YciShQzeTeZHkKguDKfDoPvM0kojO2z5jSHLOY5FhXro2RLz0hGO8C7DC6gxJsnTX0vT5ssSWFqXdOxSOcRiQRUWM8FLLoUzoVSbaV1bU/j7LAIUsiBcYidqlKxHPzKczoOO8qL7jmy7QBbzEmSfLcPE56TeGKOcshxFeWhA6AV42eTgmwAScbNdwfOKzFK5GWfquBt0iyViL0u7Nq5Q8j6yIMf8SlnWzTDbZo5e9ZcH291lGj+9dGC929pdu3EvcPpt1Py+t2wtih+Hxro02DorBBEvInPQtjbfwjbgl5yyHMV5oxkt2tw3kaTzolut8TMtBPkl6v45iLXhbi9LuzaqUPo+siL4uImkcmWXio8UNgaz1lAXa32cZoJDL54X38CLhaVgWoP289AdSbhIgpOh4STK3hm/3wbT+BebO1zbP8ZyzHMZ4AQG3u5DdzeMXrhtD04yX1oWEPH1Bhxq4+m9rUda9WZXS55EVMT4/Zm05z8SXSFowCsmefdT+XssAhVw+LyS8An0QTWKfU2fh1xRe7JnY5Lwkmbu1bE6FCpZUp9tzNRsjXfBEt+Qc7hDS5jDKC015ye5O1tYhFYAXzv0bOV+L9y7P1X9bi7LuTbskex5ZEYO8rDtb7slkA3d9OXeSJovb32sZoJCF8CLhpCIp1klQG/n+MV7CK5J2+IFlPxpNb7nMo0ewlmmAyLflXGQ5wEW0lBfvDtp4Wri7myalr0F5It0Po1qUpk/XCkmxrUV596YNWl/lPiwuYmg/jOxsuScTfgVwcxClyeL291oGKGQhvPhese8pmcZnyfToBF5gx9KIlyzzOKDhyflabsu5yHIY5UVmWwPju+P4dAN5WGf7x9LaR9t2u7fulhZl3ZtUKe+yrIjB/WPBlvsyoZHZG9izZFH7ByyjA+byeanBvgpedOFsF+GuwwN1gcIUXrotuTxef8kyj16nRPacj+dcZHeM8hK2kNB4i5i/O+w6tGDSznY3IuHF7AzO0kfGTGRaP563KOvepEo9XZYWMbw/2dtybyYbd9heDT8e2P4hywjAXD4vLmR2/tb0C3jw1hriUfskXgpBoo9EAi9Z5oX/Iqlbsk/Ox3PO7xjnRW6yrefgbmBM3jjc+oP/ECXs3OQyNr423dANvrEabVHWvckNfV2WFDHy/Yuz5U1fJn4dRYQbe8oC7R+0DF9Ie/n7YZRE4ffThQ+B/bcpZltj2Gwn3U8i+tNlFN0soo8U/f7ILPMwdxN1s5icc35H9zkz7fZldhs0XbEy+lJZwBbKrspmQ5X+fLL70FHCL6X70vsaDNUvbVHWvUmX9HZZXETWRVmutO3rd/hUxFBZXfu3WQYV+Pn3sSa1a+wG7BLUFMnL/yoPuwQ1n3GgF8cuQaFQKBQKhUKhUCgUCoVCoVAoFAqFQqFQKBQKhUKhUCgUCoVCoVAoFAqFQqFQKBQKhUKhUCgUCoVCoVAoFAqFQqFQKBQKhUKhUCgUCoVCoVAoFAqFQqFQKBQKhUKhUCgUCoVCoVAoFAqFQqFQKBQKheoRY+xoZVFKZXKJMyZemcsOt6BQW42zLEu+PZlKdZz6CFJq1STGtSzpawl//S2nJoW8RAs9LWnzrE+HF1GVTufDS48/3NpMxra/pPSrjKH/PC0Z+xQnw4uy8opTyutz4cX5Q9a81quzCa8OyoZ9/wX4zzMNx3xApoy0ImagYt9dDTNWoC9zy4sglUpyyNdaqEzj38GmQto4eFUyqutQa/vk0hkrI7qaMHGhzKzUqah5DevEx/aHc/DCVbPksBNB//JG4Rh3ARnpnrx9d3Fju7y7TN0RPSgvFRfQpnyFrGGKUAkGjJVHiX0KXU8WEh9EUrNLqGZ5dl5QJxmOVTokE9bK1JNPeRHdZVnpQ4VV5cL1hh+CX40MoRkvNdfkEuVTGmWfBh19tdEVinlR1WSUGv+i0lWUVpOmNCaNwJN8uPeHgkW+TPk57fuUK+bW8Zk/RNPLiAhtM51p/DUllbvXHinHLpVjL/3N3rtqr2/7x/gX6GxRRwnHiPExxlKheXpeeHdZJa7siMc6mKa6IbO/sJ1DUNWifRWq7QBbmxIVZVdNGlWzlO4W5l3kPG9zcnvTpIOIGp54X1Y6f8h0bXQKQ69rmnrd2Oo27lz4o7LojnxP8M67qoQ+CmC2fcDZoo4TjlH9iOrCmVbGC7jszI6FIcbN6gDPqXF2QnNerJfjVZegLHJeumoaC/X3zdJdq9umf7hl6xF8mXnpE+MEjfcW5lVD1ExGU4XqqovKRXD9blA4qd9I5d05Ke1bTNTejxrv2hicOFUjS9s+4GxRx5odK31w80pe6P2KHKRWZs6JD/Cia8H1iP7UeIG+zBboQ0LuhoKqZZSzUF1uKic1SqWJ3QrRuVBpW+GfAbVDTX1o+pyG+THnbNGWjzY7Zr2+ehy11E8v5oXYB6QvNyG0aNzd8/Pi5nz6eTHG1EVbovQWmvJSeV5sXZtJS0yTeFkN8wLZtLxYF+CCJ2FmGuH0BAu97w6JAC8j8GjA4+hmW8zFztmiMR8nHCOc68ChNg+oZpV50nosQxvm3ozKdM18sggRgZvAquaPx1SFGh2OqDJEV7IL1qtgMXY0b4bPrPTTEqCaxMQ91DRESv9Snp8XBoYOA7wYL2OSUbO2RCAvzCoMVgTkpbI/NiO8dM4Wjfk44Zg2fWEQMCNJywvv3m0SLDDwcPVg82PgrVpU0QS3HyqTbrbYzidXQ4n1+7cK980DTM/8WOPmx6Avg7xom/bD9mh6gnhHrQMx0Zgg1LnzQr8takClv7H2gV2INyUuXR4xHGMg9G4I48I+af3siA269ZCzatxQoTLrIweskhvt143xX+ogTHAbZyLcDBq3JiI4I42tJkgcpTD5HWxlz/Do1l+gL4O8CDdAtL0suvGLdiGmEaTQa076Vu628zWVGamoi5TRZLqy0mEYA+MziuOXt1Ajim7qVdDOxCh4GPB6QepDoKO2Y4mekpXpCF8H5y2EpkrWYeALainBbVTOR3Ma14H1fejLIC/G35Ei8tr2TUXCbHDuPrucI14ki+aTgbNFHVlMRdP1a7r+Z7mq37TGVIf4x1x9yMYv0f4x4MsiXhoftBEzzQymJ+xoXb11SBVutdeIz85NAoTtFtKGzW4SALpS1LF5iQYn2/XtfsXemJfyoNFWJp7zUsD9ydt8WeSd3RV3SXS3hkOVHe13wEWvK0UdU2ptgPNX9f6h1l+mA6NqzI+4VJetv6BQ06P5+1u2rBYrXviyH3m9Qe2qK6VTrFet9L2u16nq9ffvm/r75vs+TT7pB3Lw4SQ3D32RWm7L9+20E+65g/NSL85uNlcbRGWf/jvh7tscPiJdL1HfZ8mlvrrfLKvfFCn1SVcQB9UHUH1ft/OM9994PhnH+6gjTMLerKp5ZkWrBfKC88mLmxO8Xd0gL8gLajIv5SxPXe2HWRwvK4zHkJedc2p+LqzrGEP7QV5QKNTheSFsadxxDMeQl349P29LQZc3n3yL433kpYeVL0DPzy/qv75kC5wfWyEvyEusF8XIQ6QvfXp+bhQvzxatF3Ua6+UyecH1yuXxcjPCy8tzgOVO6WFEX36Xq/eDP/YjpnXe/gV5QV46Wl40LXcT9ev9x78eB399mIjSOTGE4xfkJQ3ElKlfK7k/I1JE/H6820X9BJ0DNgTdy1lKf9ltJEU4Kswf87MIR13K8Nlu8+/qP3zAtTxsxyTgcvfw+/fv6enje3sB6iYY8Amj5hQtnSgLR4X5Y7ZScnNIJEzJxngxw3ZNy2ts/tf7p/e/duLFZ5HAE/mbU3Q3Tc0oGt9F8VLqWIs7ROQALyXPcXmNbzFm/ufXx0/78TLkcgI1p+ZpcL/lBfJSB140I1N42YEW418+rt4/zsVLl+01oMYwg7ygZuDFRgasI0Fd4xofy4shSYCUg7zshIvxL4aXmYGJvM2JIYO8nDEv3AzyNS92uJ/4F0eKTykGeXl+7cjF6quJxx7vvl4fUNDNPJ8CL7i+f9bxGC1YOPK8VMLyQgIvUThm5pP53rgoXh7/+vHr8e76+sDABGbeHhl+UyEvl8aLQkPzon+oiu287IiLBubh4fHQvMDQ7MuJjWZQZ88LaSo9avHjfd7LSxSPPe8ydrGG/PjX+1+H56Wj5oQCM9SFjPftLzyMZPrG+9C/7IGLmR/7dSReAjEPb7k2w2/uMR67KF4Eg/6l2cbL867BmOVFrb88Xl8fmxiDzMtbIIP7LS+Bl2T9RbkVzYvQ4xfZt/4CeFGDl13ng4/PSzz6fwsvg/PJF8iLnx/jIT4b5OVld/eieSmPzUuGzJHdDM4nXx4vTLj1F2mG/qO87IHLtd3Pf3Re9MTcXRSZHdHPoH85U0m7Qlm4rchgf7LwF+2/omd/cuDlZfdozO3n//14d/0WSjeafXl5eTlCtzeMoe0tTWE+2Qz297HZ35qXtwEm3jPjmcGpZtT8vDj/8vxlL/dyreKx8v1bxGMD4xkfnB10QhmnxxbMy164fFW8fDri+ss0ZvzM2WGiMxy/LJeXfd3L1z/HXa+c+PlM/MXZ89y84PrLcnnZa/RyfX1SvMTgHAoa5V+Ql2WO9/d1L2b88un0eEnjMwvNTNNnGI8t1r+87Ote1H7LXz9+PZ4iL/3Q6PmzPakht8jLQnnZ272oDywfHh7uTpaX4UHNHr6mQVyWysvetq738//1eMq8JNR0u2jwqwDUq3nZExc1P/af1WmOXybMBTzYPQEvrxvYNDVD+1kmL3u5F32rn0/+en19bsjEK5xm06aK0iY4HNxvuVRefu7Jy1fDy6f3j2fGS+9mGsDNy+hUGvKyXF7u9rB051/K8+VlcGtA53CQF5QW1esv/324+/Pnq9Wfu6+v1J2+9c/j+/KvkMn5KplFC9z8/Jkxw3H9ZYH+RfHy45/fvx73kLKux8cHvT/5nOS42Jbst9U///zz35/x/k1+Xy2cF8IWoroOR7er24/s/Qz68ePH+0uW7STfd+pfd3CSz9f8f3he6mpxul2tyvrjDNLgXb5Uj927nitvb0/5wd5XGD0dQPfhe+Q9Va/qhUUjOH5ZoMq5dtlWK7Y4Xijaz/J4+XceXj4ukBf0L8jLjvpZrT4ujRdcf1mebubyL/xHg7ygkBdUvxqOHYe87O5fCJoPCnmZqmq1sAl/ygiaD/KyOy+4/oK6eN0jL8gL6i14qZAX1OXzMtP6PrthS+MF55OXp9n2wxRL2xzCyxvkBXlBTRbici6SlFKpD4Q6EPaaPqTmFFw0Cf0vtKDhCOMx1JJigbI0bzemDsqKh0MlBi9SdUS5+6UsynA0Oy+LG++r7ytxf/KZSBNBACQk58VePB4v+P0L6lQljM1LAAnv4UVfPAH/8k3ps5E6uChecH7sjMIxG5ApNFhTlWUdgq/4or9k6fF/gGbkpe5j5fPn/wFpaH4iL6jjqoZBGDP4pLy4izkvJBrua17m2QbFWcqdZeUdlEHmG/KCOn44ZhjRaEjWw4u7mPMSh2Pz8dIHy7seaWQughheMzTFswnHaguCoqKu/eAf8OIvHo+XhjSQln5YjP6+FGJQZxOOVdTy4If2NOHFXzweL3B+bIwW52QuYBzTYDh2NuFYrX1MFc0nZ7yQYtp4fx5ewvzYt620OGLO3MmQmxvcGXEu4Zh3IN6ViD7/IibwUs3Hi/Yvz9NoCQOZM0ZGjfeRlzMJx0rvQfTQnptFl2S87y4OxGPlIXipXkPL+SOD82NnFI4xxiodkDG/PkkTXtzF4/FCSvYtmz+ehsxn5AV10HCM+r8GDQ1FLRNe7MWj8fL8TVn+3+92kV2U+fb8/Iy8oOb3L269UW89FsLsRBZ2u7LftQwu+ktux3K+P3kmXvRyy260eGQMM+cFDEFjXJxm4OWbjsM+PD09vdtL54gMaoG8/Njn/p9+0PL0aU9eOjdzHiszlDE0H/Qvr43C/BB/Dl4AMzh+QV0YL/F2yrl4CcycemiG378gL1NjsG/53uM5eTmLrczIC/IyDZbPfessT08f3s0s+8EMxmOos+Xl2y5rknuPZk5y3ozc3iAvyMswKdaxDK6yfPhwQGZwshl1Vrx83uZX5h6/DHBjfA1ygzpJXoxP6eaM35aX1N28cZzG7yuMxxbIyw0ZGqlMJOXIvGToGGyOv8aJ4330Ly70+uze4dMH9v9797R6eve/d2+jzuMc0d9wnE9enppydcv036bhnP+txT50GrHRD+BfffC0+jTriF9ltq0KcWVM6r//JoTwo3wprNZfFv69GKmWp9vVqqxrRoj6oEZ9UVM+ffr06WkXlf/+W+5466u0pQj9sUJV3R+h50rVcyf8YO+rw3tYsjixm9WqmimrRfQXM/+oP8z8e5rtN5XErw3edP1l68umxgeEQl6mql5VC+u6Bof7yAvy8orxPgKDvOye0cJ4wflk5AX9C/oX1JHG+wtbjeCrFUf7QV5Q6F9QyMv8DgZxQV6gBKVyckYmsfrnZFsqKRX4vFGH44WX5XTzN4lZWb4Ss70k1BL7ZAZoWc463uCMoYNBXvbn5VW37Wey5SsYmJsX3M9/vqI7v9Lnmx8LlByPl1rxUr/Z8AV5Od5bUYnNiIvKTszAiwoxBCtrIUmpvx1sTLQjSFVWRGfvj4iyU3NFpZdcpaF1WTNNibpQNOpXFSfpGeayJIccMghFi204Y1zXQR9SVRFGfeXVDzpqayjhwsRPlJi66xNeKYejbmNSt0R1IdGYuwRT/AvOj50pL+ph7+okIl6YrVml39vKDo2jEJW9JvwRL2yq2qTXmFB7wcVjrnnmx0rfd8iObGyQ5SpQmWusNugaL6e7mZpaMhOPuaqGKpsWk9ByERJMisdw/eUseRG7uxfFyyriRb+n1YuWaOMyJqeOGvVZmTKqWl8TnBeNKJQHsngwzkVdVrQbvwh9L/3Z6PO5xwxpOFab/zUWVaMrToUuUFaqcyNeKvUNmakL0z0luNAMUW5u02wXeuqMwwQTHuN9RRdqwdRPNfoD6QcEwh2YH4T+R/9kJEU4UjeozxOFS0+zXFxOIjsOWZh7OW/gKATMMwmQo7sIDnUuRZGVCCZQuxRpKal/ccMPGnipjEEqJETnxBpO6jC8L+wP6XhfU8P5rG40f02YOgqLhSlXg811IBjzwv14n2jCqR/8m9tsIygnDCZAjUi/7qUbBxDvAhp/QGwK8+5h3mGrp8HCkQtVVCDsr7Eol8IE9SqEMS9be6M55j4LbgysNMMG9/oydzD76Co3rrWFmzlUe2gCbW5ekUmJrhR7RoIHSkrZzottiw67vK8QNQy/vO2lvEQ9cSg/TTjpDF+XGzp0gBfba7VIeWH+MfgECMUWXhpnTMwH8gEc2++jvNS+uyMrCblYK3XXu2MJeWlKP04wvoEBkmyZHSQmka9HA3npL7GQPqOklN140SYq+QReOk97sNkxN5CCvHBT7AAvyr3akX3Mi3ZLIkowAdebm2bBvBD7GjfWIUrvcbgzuXFe9LXKjDchL0kuzrq7YxtkQ9KqsJ4Q8jaWTSJw9FUJ6tHx0l+ioyQgXMFVi628kP+zb649jetMAG6Q7LWDGtaBdJFWpYJPSOgI9VWPBBz+/+96PTMe27m0Se+l8ZyzNFcnTeeZmycY0MPzoeRdlgouEfFSZVRSq/Oi3R0fTaegOmbrcFgh87y4oNFour5s8gJBc8XJf+Al+s7ugEH5/kh5YTWTrFbaa5p2KlnnRbJ2qRAGWT2CImq034+C42tTaRsH8XIJWlsGzzDBSys3ZwwKnmtjC7iG3QMGZDB4KXBUWIRoxG73ozSvaDRFZypjB1W7yiBeIFu2dS6HpVJ4Uagee168L3MbSjijqCCGtNp8tHxfe1ugAy9wB7m9yWDX6rwovKesbPuXXGXxAamevHn6Ah6RYLUkTy+8BhYNXjSm1VikxCWJ+Yjxg8koXhD1aWi/DCotEDQKWjAK4Exc1CpeJRc7afDKB9qoHpnxvHReke0Bbqhdpas+1uIFZijst5OchOUlxIpKRLw0NyCedtoj4xOPFY5VzrtFvFT4i+WUD+a65V/c3mb+4g4OBwziRY+ZFzWh+QWvX1mIa8p2PCZ9zCS9olYxL2EUhTMDXiXzwIQOSQpB4UqU9Qha+INw8DLiBS6imZfuK9YK2LWrtPzLOv8b19nwgTWTksYGV847U4cj1wJNZ8+D7G4JNX7r18Ce0fHGYw4BnmhD/SoyjsIh3s97eHFTebV4LIyioniYlv9lTxMl9SKaKau5h8oNpGhwFSbWXCGCeem+Itn7wiU2ojEfl/r5d5VSqbF+c5dEMy/Q7iFDYFNGKfkaXmwYoOKQycULbpS2f/m37V+gEyNnv1LzLyVnKiYKyrv8S/cV8RjlK83RVVw8dsU/+8e7l3+82JWPj48E/D6ZYySVwWzEt1dkLtrakO9jBiKjkMlpqRtlc/7iQxhZYRW5lb/AilDR7EDEJeyTbpQ1V6Q8HQdpXOWKefmIGPkbye3trf3rqNkPG9uSNmJeKE4psnjOi0u1so8Xu1QgZhEv0SiGZhaxWrWuPka0CbdeUmKN9bEqqj8zL2LSUR9rXpHrYyqYgvpVWvn+Xk66uJC47otAaVBSE7c5eJtdrjPe+hhWqXxeLwuvX8KpolrHi1NP4VDLZOClOUrP/IvJQpZSn38pwwlG8v3JjvmXNVc0WWO5iGfdiy15+fhYY5TVNL8MUBwqt/0SYbODsxkvL2hvca5SOmZgIiznwMYVBDbw4tL9ON838ShD5vd1Fmfi0fw+Nh1YwTo2z46q9vz+uivqcL5oXIV4UdsqJIQy7fLu9Pms0VcUet1uJw1qEi99AuEUpd/SRWYcUHFqIDbzMpHcP+Z50fEo9W6u7v6xSvhJUgRG05A426JclUyFSRftiuB8jdYVfceawnYAut2qcZUtePmKghzSraaXPkeX4sdHPfq63V38VxtIzXh5Ma752KbCrl0YNRayeNfYW9X7k0NbcNyf7DwDbTDxKJSR5P39ybU+cupP5gHoBnFw3NTqT25eka9SO791lWG8eFgi1epA5vQBGN3W7cFkgz1o8TK7S++LHU2Ko74Jssd99fPyAWrZ0kpGhk2xVqfM99/fD89KgxoXeK73NWXC5XguzFr16kfy8vG+Vi1ZqVCjiundKd3KvtHXFp4GA7SkwkmG8PK+2Yizk4H62PHz/Q9yK8dGpVE/C7WARgFdJfVJvDTzlj7dJGI+Po5dT/46agQ2gJp/GlnNePvHEi/rkoRB6km6tJo+fR2/BnZ7Nvkb18/eP/4dcX0s8bIHLaxMf14+j8HL1wWg0onNu0q8jJKX7v5kyhO20qR//j18tnKWCGwYN3+m009wNV9JiUbvX77et1fTP5//vB+q7ffr/cLcStf3fXr68/c2CtFSDW2cvHxgJLalub19mX3/+XuAKcyvn8AKB2atggC/PZDguVJRdV4+3rcPxEhnXqaWFwzs98xV/tm/teUkvNz+6Wvi9Ph8rO1STfKD/Uv3RP7gcP7b/r2l+Zht5/c+3i85V1kTj82+tyxFp1znCvzLjPP99/o7I3/jCbu1Eg56mT4Fu+r0Y2CxeIse/L/HlMGBGBUEbb4fzhl2hcGP5UeIFuMT+77YkxCfn59q9Wcv+Z5+vzQ2rVAUymcQ2gC7Xl5e/vxYeZpOL/nuV5/HxqVUz3eHlsOPeKD7en7GP8+z6XSW46an/OXp6eXpxf59evr+foJPXO6Wl6dv+sxzOP4pL3La8W3FHxUt+k387xv3fjdG7brSBcrLi31y2dMly/EdjLwy+bL/rRWyEfl0VqSodIuSxBcJVkp0eiDjq4/NxIG8sxjZo9MJl9HXk/fh5TM9zSQj4sWEMI13qnJfiNTVPjk5OoeaBOvJrNI6A8kjRPZ+J9QOebVPrqufn14hH24mTJFLmZmDuHeVlPm0/sUqt1KWGHM+XtDF7a8+lcp0dez3vz+ns9YV7FvnpfvaMstkP3OFLLKDKPo1W6bL8i9TET9y+0eXQI0wxItWWud5aVSmqonfI+1C4dRFF1ku3MvW2m5XcmJEbndXOKSBc+w23JiLvl/dSiH3/FJlZu8vN0fnpelfDDydbXgxZlLJSeLlp/qXCfzMWqOfySvkRWUUpmUIj9tjjypUTieKTGk2kuSidGXBAHCc4ihlz5a4scj6fnV0cXumTcbqoKwmx+alFY8h7hV+gpWA9A8MizUwRilp62nwINDMOLsihf0oI5vjtlPyqAVGx3xSZG8w+rKWDBbAQ6FlooVOk5bkOLxIeMgGDDOaR+JFVXZPWQETvEdj1CadTa1gG1pzdEIV7S7tH+ClsmpQ2ZEkYiD7raTJgVVWocp+osaByxJeeayilEWmv0RWmODCnL55nWE/d5T8ZXZXtsIxgV8SniRaGWt6cntLaGBy+/yslSngoQqyK2h2aJ1sjrM3LhjOCD93Umxv8DkpOiFzlswvtE1akoOJ7bcUtWDIBhSVBq0MvBA8sMB7StBP0kN3FgUfArfjoRjN4e9aws+daQhWCmEGRBWAp1chtNOZBIjstb3G6eD2lHdhrIesM97PHadANmmHY9beiDgey+0fayxKuyZsYmbIphhMDGVpYYdnlnub4+yN40UgeHxSbG9iXkxVxAsdJi3J8fJ9IeGHyIXo5MXv0aSodJYGQRAqgUauxov9J+CgiQRs8qqfF0l0kQphRmCMVS3wNaw8qB+4T0QujPWwpjNllpnTPEvrTOC+qsCLdMZEu2xGCvSEeBDXU+Dbss1x9sYXW2gQOim2NzEvjYUOk5bkePkLh2Kyixe/x1QYA/mjJxPDJheiaFActLYwJCoFKLM1r7onCQ68eBWykOVC+lKdUx460jka78JYD1lnPLdHoeMuL1vVsQyTr5gXAcZE0lOSGTlNftIRL2RznL2p8cInxfZmAy8dJu16he3RWXkx9AN18OL36Fz7HN+mGdpmpjRaYYtpaOfhuAKHhAxCoYkVGMoPisekVyHMTSAd0O4B+Ug/8MIujL8B68xReWnNv8C3hrhQBF4qunZVES94P2x3bNzFwZu3Oc7e1Hjhk2J7g4ahk5cuk5Z4OWD+MmvxAiFO3h2P8R5w9vYXJDVBhS74TKu6FZlCux+GhGNBmU3eXyrmknYxiVSoKn2I55Wnzgu7MNZD1hnv547DS6OerLk2VmEZHci2GYolWeTOv9hURUOKRTam0CXsBcDY5jh7U+OFT4rtTUmFgg5eOk1a4uWA8y8z1VGPrdZWat2eeFrRhJVKugNM2O8XTe9UJGfxJritDMqqLioRmde4Gi/swlgPWWe8nzsJL6SdkJbjzYHt0BRg5YZ4AZOhQLvJxpQUM4nK2xy2NzEvfFJsbyrlBmrHY10m7YQCM84VL9S1w01F444KD+NWeWP8EhygdVmhKpFUDR3DkaqgcNJv9I33hhPqcCMVn1Q1zvYK6y/n58xN7RYcL9MLskHICyW1rEIYtFuLi6pVeI2r8cIujPXQO0j2c0eKx3Sf6tBPEq5fRYbFBZjh5zKxvYmk6rI3601Pp0k76S+oKSZ2dZacg4+MtsAR6Bgkl8xDtgqnCteVxb6DogM/ip0joDKu8cs0W86HZ+h+fRqIN0Jpoo9l/fyeDEOpcDl/rqrdQjN/OZy8ghzCVBmvdqwuVacSmIYeBgdpjqY0ZbHHgzPWS5aTKxTtYnPDaiYzBiej+kMPLyWHGDVewijoZt32khdzE/NialquqErieVGuCSOK5+D0k/HippkDLHOQX/bfpzr59PJP0UOzd+v3BfPCXgTVLFT8nOb18KK4maTGix+l8rioyh/hmlGYF+2GEEHptefFuFngWv6jTsiLj44CLb9IVtnq9Yr1UG95JfS6aEwO4X0vVFixlVOzKvPVIKeZdV60p8wNgMco+hn9XHMYRVAnh1R2YregWEqSx6hHYNaMq0jpyV1JnyKXgZeSIsdoXjvmRa2vJx+ClwAL8WJ141o1Q89m5XawOFMyn18xNC7rNKyVLmQyPsEo67wITK5hm0v3UfnLqq6vYRQYvfL1e3IhFczR8WCSkFA+3ycnIZiXwjWxeF6glER+TbnUvsZLPd2v88J9WALQ1PZ9qAr7r7Bby4iSmvug5lMYyrWU9LzAvMHrfGn9YL60SrHIs5X9/9dida3tf6Kjn38DLfOaKSFqrhAZ0k6pa9k76R8tFe14zHc3wWGERi5rvPhRZPAieJJvd8hkSPdN1sz3gVPixdQq0JGbUyH0asVjcg0v3IeFMwlQDS1wfgC/T+6jTJo3ht4TwfMybs9yvspXFhCLiT3MLcCGa2z/G85LG5YYmWvkRSinsRBIFa7PwKlOvpkXZkNGvIRRZKS9uq72gRd2R17p+bLO9xR+EMmdQ7vxEvVhgZey08lYz8B5ei1NrWdLUJQqfDfXK7gTkGWW2X85xmO4YXGQ9r/XIBfCy7TchxYm5rqQKbxJ9dUuMKsulNKuZWgTL7bliZN15iWMMsi/QNkHpyF8UBUYhNBN+oAMh8s5f9maF+7DgsZ06J1VUcVhMmnOqbv8zfEynyMeS4i/sl9ZtnC8LFaHaP/jTJlj/8vwL+V+tFwjMlks+OICORtNalg2eWnm+zjfWSlaZ16iUfLQstvOX7SbUvApEfNiWO8NR4R5rT4mJjvl+76V2DaSFOijCmzi6uZFwa6SeSE8bAM9EBN4WdkN1uE87tX+52CJdewCFEzo/Wm5pO9zKF7ImOcws1x5dNQkThPW8yI9ZkFf41FgT1FWm+pjVeZehQi8OAcmvSNz+ySXpnfjhfuwKCsCRpFl08ULNXRNwJGp10/HywI+4U+eLXnDAjYs5ru3/3Up3c+wyXjnv4bI1RBDr3M4f6DK4GvMxCfs3byQR0LN44zH6Ws8ypD5l8INQbMsOAidJrmFnD0TjqB0Y67FL/XNv/g+LHenBpyXLWR38VKigynAYqzmy8DLEkpkkMOAW4ENK1sqyxaLXdv/NiTL59WweI52za0PpYW+zzUEZcbPPkrOG+xcCoVS0cTMel5q7x86Xmqj+Pn9fO38vswa+b7i+VMMx7CJnAKyqHywCy++D2tCf6n/yjWoN3ihACsr/1tROYzDLxt/0QoUxlYADmxYLHZs/9tgos/sY/ry/detcPkpLrNHcALQYH4AepqFgEo5OkwPL9ShShOKpOpVbRSc4+jpH9PxHIuDruAyN09ayt14qfVbtrutjFzbqwx9nNaGLmq/+mLRWAgb5jt0cm3WubOqWE++vy0u10FMFRp8Teg4ph7hzv7kRiOw60/WfrPh/H0SWp6L6I2mQf3JfNmKR+Aho17len8yLR2+P/l1vo06vB4Wl/OGMRt52YGWK0v8jxgI973VftT5pb14eZ1vpw2v/22Ly+Ua5U3x2I64XElQdmxe7Pvdk5/Iy+vWOrGV+Ryqc2eakNHZuk7onWnxxCRkLlV25+W1jsvybbkYog6DdWELGucXFcfshUtyMpctYkdeXpvq/Da7W8wP52Jet3ReF6Nie9NyRdXlxMt64/82HcbLMGJ2ULpTq5iGl2bbtBwEl0TMBcdjxUEyl6H+ZYgqvL7upHOnVbF2fez1cLSEhv8EzaX5l2IHWlpKsVjevC0Oo9l7KN0p8xgxvSvbruVQtFz7e2WjicfWafP8c7E4RBVoTxN9ulxZx++/HNa1tNuXEzM/kpfX9ZHSYrGYb6/Zrx2wzPfWsJOol57eaUbFvWzw6zjimUnY/Kh4bGNasVU81ozQ/3s9pNZ59Trqk3t8Wz6+Ru/l/DqqzEN0lqD5Ef5lY8Axn79Nvxc7a8G8Q+kWndJ7wKKlXV3y354S4b09KM0vwn12i96v/Cv+Xv8l7T1LfWwIL49aw08Hv1Xnb2p5mX0v1uy8JKnfIn6f+Q5iT10sl63xTvtN5o+P57W1RRDbJF90i0IpBohSPcc2dg0a9HCi4P9sNv3eeOkcpHh4eLhx8sbiVm9o+Xs2w31uG++6ueEDozMPL0sU98HyFi59UKFH8T37hsW33b9X414HyE14lPjxnNPP0/nzHp+X/CQS1DA/4QVbV6XVbDqdWVo2nbnCf6uW0JD0qYq76SynYwdJNMSKV911aNvKL/MZ4UZwBy3RcereCtom+Li//xSfn5/398eyNHhbz9NpXuTFarVq7uTvFXatmk9mRTcN9413en+/WnVdZ+WGiZ5U25rlnepUpODpYuYrO6Qc8Dr7VYnueV8sSaonJ4me3Ob3xZKMvp682b8okXhJkngZrD53I1OfMuGSeEm8JEmSeDmCeymUTPqTeEm8pPwlyfF5eS5k4iVJ4iVJ4iVJ4mVvXtJ8ZeJlZ9Fji8d0lideEi8p309ykWKkFROvmtpOXoyPkizt0yq7tYoW/Ho8clVqbRIvSX6kPwdRpNO6wBXioBI5rAnUbANLfE7GwmOE06RdwNPdAq/HI5s8uqTnJU+87OaZk4E4PS+ovZViDoTXaiu5dIfl3bzUTuvmpT5yQYv6ELw8svDXmWVjqyenfP8MvGT2oXulBl2uGBdyBKjjspOX2mndvLQOyWP8duXl0b5uKe6dCKH14wj7+VM9+fS8SNTjEnS4rAwSZIT9U8hKKsRFeufgeAlaWT+tk5f6IXjF0r5UtR8vj8CKfSXwtxe7cj82XBIvZ/MvQIjhTdp6gCJkGIIis8CL8Ol+/bROXtqHFO18P9+SFoDld0PeHuy7sXpkvKR47By86ElwIHkrwXBbZD0e8/D4g1SNFyeyfojLX8Qe+T74lhYsIA/2feTn+zERUwqR+i3PwIsLyuKMJPwO6BLC/iYv4bS1vESHcCVh53js8VF0+BYKyW5ms5uHe/2Yftgkx8tfIGASG/wL7JMQoR3Ev0wqjUSa3XixodgaWoiXh4eHpRgNMf8bXcZ2fl7I7m/IXwAgnEEx7Xx/Q/6ipdQd+QtMXMp6vDecl020WHme3j0AN6NxMSnfPwMv8Ee062N2ehHrYzKqBu9fH1NAotmNF/n4uYmW379vZncPcMRyLMTYfD85mHPkL+X6+Rfhtxe1eGzN/IsPwrrnX4RLhuKJxYG89DgXSPituNDsXjw+joGX5F/OwYvYML9vl3I7X+IDsp75/TYvtUN44K3z/Ufd41yIl5DMjMHFpHryOXhxkxa1/jFDbkUYzjV8ztHTP9bmpT6y3K1/DJzL7z65uXuOgBkBMTr1j51UzJpGY0oXcI/hHmPuUe7pT0bp60+uTxr08zLEuWD+MruJ62X3n9dOTJlwGZ/08jLIubR5wTQmzcYkGRcvdj5/OQiXNi9Wrjrx13mRHEziZSfnsoaXq/YxKd9PvDRoefxcDsXl4eE5yvd/jyDzT7wkXuq4fA52LpaLoigeuvdcKTFp/mWUvHyv4WWLUIwcTLd/8fMxj4mXJFfLy7a0/H6Afsu1e9+Wy6srL5fPeeIlxWOOli1xse6lK9+/eieTZPS8PAItv7eVB+633CT3V4VM8i6JF7n2BcpB8VjvmUtE5vEaXkzU0CmbZMy8oGtZ7oIL+ZeHAcdxr8yPdzSpn3/kvDxi0/5OtNii8cPNwxbnLoGZnx2cpfrYGEW7+lipxed9kGWfNNr47ZaHh/tlG7cHfxwfTMe8vb2tbHD2+XPLZno6+9/IdUcdWgRKWLoY0Rr+WSlm00xooYr82crdUJnN7m5Q7En0eTe7c4sDhS/3/FwU9vHocmuBbmz+xMX4Y4jsoyz/U9OpGDcv6nmz5F6eh0p08N2lCd7SbDqdFfYVmbvnLOzJ+s+l/1nsEgyU4dbaJfz3fl7zGCx5MxB4M+d5a8mfDyT+l83jpfbPzjtyfJUov2ApfjaM8lzirXHdNLsFNZs+S3iXY1vDDq+kRZsmajoTzatsIXovObI3rkUMfgkv2x9jFDsLKH335hHwcrFVUeTlEOF8NrJwXoikPomXnQca2+u5qT858bKHlEUxNl5SPXmUvDzJ9BgSL0lOzIvWY+MlxWOj5CU7UP7yPC710dO7xEviZXf1+U7qkyTFY4P9SzK3SRIvKf1d9+TS+5UpHkv+JeX7SU7By0R+jezJJV4SL0lSAJrkFPlLWahxcaeSf+mLOKQ0uGCoPZdWcaXibuAK9lf+3Qo6EjdUvCGMYWpjV27R2IbbaA+cbNwYKCY6lxdwS3zV5j3zHUit5VH8SzmdjWvCskwdwD1iX3jQTsmyDFcz41Zk5sTqnhH4aoQA9VR0jqQ9E13ALjTEsCcraLxK4NsUAjW7xHG87kk6sAyXUHRurmkUfD0SPumu6oMZWMJh8A4qGswcwb9MUj05SS8vqs1LyYu5ISryqqatGamwW1aWKpPz9pI03IGHUbKnpMkLjqIdorBGd+UHy6W70zzwIniEI+Qvo+OlTHnf1rxYXWvw4pcQFEW+grRVhV3ar6hJlYftNFzOXgHXHEptXuwohu4JscEbCYMBiZOC0aM7yNzg5gjx2OxuXPFYyvd34UUFXkjtCoqFMIwSLnIyuBscT15WBhkwdo8qQXdLQSEahnEFnjHRSmkOpzJt7ClldIkJn1vg5QoXluGN4CCykgpxkeyH6GyJo9l3/swR4jGlUj9/kj5estLzoiGl9glDVYAOkycQqK2CDTucoUHn8TRIN4qKYy+kSXG+r6NMhi9BUZ7jFP8auihu8INF0Vwe+5dcyKPUx0YniZedeClq8RgGRcYfJF3kBK5F+iALlFqhzoNC535YDK5MFuX7nM5PvK/As+BcTIbcOdpHcv9v32xfW/XZOF5hCUmgEQMK24tRYWevxhj9cW+csv//77rzbGJjl3T2tNXryzlbpzFGm4/XU8RhqkCfyDpkYfxCmhnjl/3+S+lTSv76s18RL5BPLuWF2f8xL8P8Vry4NsFUJp4XGgX3uoUIgCFBbB7zwrnFj5u+2MbzMkx/9RcPM3Q248DauXjZW1Q+Pz/e3z8+NDNff/A6eAH7UsqLyQ+fti/EJqWm7EsV2xdVf+FVkCZO8+Ixo3GuLLIvqnds4hwHko6Wgia/88cULE9Khhf5+8nYma8VIIMoIFHKiwh4wW7Ox/ELsR5WKn5Ru0gcv+gIhQYwhPHLEO9XYWHF7DmOX5hDujFH64qmSjiTWeyL0LQ8Pj4OvDxZej7XgQyokBc7dU/lx4g1AXn5sdaH7vhkfqyqHH3MhfQ+PyY70/kxHKSvsTd+CuQ5eMHKEXvSvEhgnhwv5i/FjERmydGMXAAE/thPvIRBip+HES9H9RdXYMmsv3Abc1TtZnOi/kKoqzsiZ2qO6i++1ikdsiGjzcb+2Fm8YOuKPVpcHC+PVg6ZPxC/AC8BL2behw//cX3fRfWT9f3/RfV9XIUhzWR93xQtXSXSO29RfV9+YrLYoh2yqGLKfluvdLQ8DXB8SAW8LJ8Y4OUsXpoxL+P1Y8Q6aan1Y4xKXEZLvugQmxizbxeajXnRya/WOGR88BLt6WVnLvY3hRs9goaMcDmLF02LifMDND4CgAJgFDJL5QUC/tPzxK1BTq9PHpK00fpk1+bs9clNan1yM3TaBGuUfWfhSdUxwfpk0W5+w4u3LT/Yl4iYBT6J5Xp+4GV1KuVF0fI06HEqfhl2uHwZXtyd6yEDCLzk0OJR8Fg8fiZ5CZFZHDGwPhl4yaXliIlJXnyThbplIOAlrTCDfGxCDC+P01qaW0afGeC/OolcXuIMcoIXHe+7LRPESGYWU/hHEO8DL5PNpmnxabCPKKCZMjLGL8NL4AXqL8DLVNzyeTI20QvIIl5ONTbLy8Td8wL2BXg51v4HWnLjl0RV5q5fl4F6JfAyTcvTTwD8kB87zjA7Zu51UaYgsN4SeBnD8hUtfPmZl1T6bIKXYOn/F4ZaBui+eYnWvWgSnk7mx6Z5eUpwEqz894bmzpiB98WAl8iwfAaYJCZ7RED4vti0NRn3ERua+0qcoa4Gf2yVvMQBhDCs6DeLn7L1+fTxkd3Yrs087sQamrugRubHgJfVSdX35dd+OBz2QlBECPs4UyqjPJcIQYje8Gw8HDYHsu3QuucO6euZ1UvVt6Ne/wsH19fdtquen5+r6rvrttvt+9zSZ+nLj+vUAOuqqm9P6jtl8sZtK3Nxwe29pVFe/lmL1icueSHDn5R+fVEvRLMlSLclVJQcclK3f+dYdONuUOA8XSZ+eZ6lACL6emX5IgHhC/ByvnGua8ivgtaQHzvMwsvalocITmD6rDI/hueZPnxd/gmst1ylfXnW+WTQGbzAest1+mPzVAf3YnW8wIMGeDm7o7XF+1DfB15+Ewh1K3NPaFXDomrg5Xz70kGFDLQGXmZxK1ZnX0DAy+/sy8r8MVjPD7z8pqeVmReI94EXUAkvkE8GXs4XIfn97Pd/Yr0Gn/f7/X3wAvZlJIxxo3438oP71bqN6kOrfmg1rlG8uXUtfZ+NO34T9KxPRqn72PpDwwa27+DQZpManRlPPIThpK2gtLlevG9A+Xp1evB6jfRl4cHAy92oqapK50ip/OB+YfmDuI1U/aVFNkT9vdH7sd8sv+4GqQ8M2YmumlXcTS21z9BntpuZbA5HzXBqOyflH/Y7olyfFSdGZ8YTDmG4kk3D9N52fl6qk/nkvTEpx5hMKILnJg0PhjdMjqaAnOcpXvQU5wleWHvEi3AfWTPw4mZsWxnIDDiORDfr1RERL8RN+5a4XlEWL/5K9KjdOefNj03zokj5L5OTY+12O/U/Igfm5i2Kh9MtmpHUPLKPeJE7Rrz4TxqmgRdDhvCfdANnbPDQJuRFn7Jqg070GTN48VeC7WnY/Lx0KV6UVfk6E5QRNmO742zO9ewL1JviG+Ie4NGMFMFENrzgwNFijdtCDAjcOFbYmwa1XTDrWJl535hz0YYQ4nkRRO8JedGnVMepMTDRNnpDM+YFB+aIJK4EC3me2Xk5EEaPzcrrLKwkbY5n50q+GuTHxjfEWIURL9ROcf3IRnqem2DazH0U8+IDh5bbh7rejs3mZnCOdIiDA1K1ZaIRL9xNex/16BhqzAt1wb3nZbgSrIOnS8T7aVYe/oFG2OyBl+uIeX/mmBfaxF4P8T6SiHihbmabJ7vfjvT0pYNrZqY0GeJ9vBnzYumqNFwKwrZRYyQpf4xEvLCRZ1ah+eP9jX1Ls1Uu2Ou/YmWCm39BDfBy7I5x8/Q/5oXTFC/MRgcxL4HNGG0n9hStj+BNjKPbijEv1La2JG2k+6Z7+5GX4Epsfqya3x8TvV7Pb2B52O0erqUIm8vmkyGAGbljWM4uHvNiE1ksxQtBw4P8R/tSaYNBfI5YIJ+40l4VG8cvyqMzjpz+QW0j9CMvwZVIMCmp/KDmXT+GjBP2cBu6NDUI1o8duWO6ymEmbWtnZJCasrwM8T5pxrxMxC+aFN2fRgyZYqN69pMwP4ZCA9U4s8ZM/OLcMxqOLhnvB1eiQxscJJRnzCe/7G4HlgQ1s08QAbgcZceGHDFqzSNaTUITBGjfKObFemuZ+bEBvVbbIcVUyAtpQ16ob41NfoxaDy4cXYqX8ErkJt42s/Mi6yu79/crOmE5Ltr9LLW53+yY5mLTsmjGaR/KPOvj+guxLXFqsh7VX5phl9AEsNAfk2cJKSGu0qi5C4yciEYXjMcPIbwSZDn3UP2eFx2xyATv29ut4jIyNTMhQxmH9ysjd4zJOoV1Y4ZZyJzbRVO8mPkd8HKivq/dMamQANaEuYGQF+2OydZqXEF9X7ULRpfiJbwSG+7PFu9jVY10JZEb52VEzW+xobB+bOSO0eE3VrON0dbmcrmrEx7xsuEjXpLrx3RPxJoctaVtSMBUihcarDXAbv2Ycss24egSvMRXgudbP2ZK93cByaR/9rt8MuTHvJrxyt7GrhMe1iLrJtH65CY4sBmWIU+sTw5XP7d6fbJohwPaobnu3y1UboPDGrseYBhdMB43hNGVqPXJ+Pf1Su2FxSX3t93u/qj5OtvUQP1ljTqPF503jvDY3XK8n2NqoP4CuggvewtLDMfrnfJyflAjIN5fIy99ES/7qYqk5uXhrjVz/gy0cl72J8v3989LqaURYF7AHzttWE6U7xfCS5QJOHljaF0DMMDLWbAM76QsSMNLApAfA2Xzss9bRLlbHC8/LHb+u/0GXoCXgpDlyB9bIDDhO9CxqQH7ArxEKnpFUubHXt4eFq3XyNj8D3gBXrxd2Ze+yfK6pHg/i5vd++5UeANaJi/P216cF7GM/LGbX598QXj++wMvC6xDmI3si6Cv57z29Sp5eXu4vffFLqghXJOfdjvLDfhoixZ93tbImhVBkXphgO3OkuRltyqlr1feQYQQXUMxk9fdvKoq9b9Sv25MemTq9/d2233r65Y/tlIv3cuE3v2PePP7qNG7ktvx/v7+cgt6n2kg8qnw8vZDm+4lvtE/fhOd+TJyv7qc+VR3/T9wTUBSnQFnYueJA19eytrfw724cPtL6uIWjqL1iVTbjtDRlf+NFR/ASLIj3nUseYKJ9lPjKWsuz8vLmhf2TxhHf9HfxI2RT1c+x/jlAbRsPJmCYOMq9f2xFaZ4ItH2jUraT40HFQbMtKy9QGWPXTE5fPpdiznGjy56vaB5dWCl779M8tKlv/nS+VPoRoiy/nHpO16Fw8foUNg/8HJfCTI6T9WAfnfgAZwTNYuL8gua1x2T/nbpEzftcWDOErxgwnnBCah0z4tf8kX5RwiVMOekYM7J+GJiRJQxcdxaRhgEEVRw/xkpsKiIlX9foNmEakZIxcoCngI7gvpeFnQ6ktmcdIzwmpU9QtmWF7RlnDGWPeMwl0mMiROg7fZooKRnjPNum3tHaV0R8pw9HszkcHhFYOJeyRermXTGUJc/4QSpt/m80E6HxDwTGFSrgaCuiF++zcZxI2pWdoOYruWS5ISeXG8p6ioTANGp2FF0DOfiroezBWCuI26+cdZlP3Cl00XqdB6MH2+3ySJR5wEpqIGsZFLL53mfPX1QR4oWeaFTj4ZJXnhNs58nTGYHDlUtcpuba+4hiLmKWGW8iG2JS0zTk0jUk5OLdCURRlXij7FaiO9s88i30l/q8vuXvFDpYtFNrj9m7maBv1ozSrP9Q8dL30EIcxX1ffF8nnzoin6Cl0N+/CJ7YV2Bd7ghz0K6M9kHyLmPJJDZl4tkDVbmB9InECzpRhWZR3m5cnELyzV50rHdS5cYXry5kqrqZ7cjm5cJ+0KrqqR3oZ652fNfnVK2Lyt5iC53vhFTmyoKGFjBZBZ9TzcHWmf7V6SuZcKiBvtyVX+Mz2RfSHJKs9KHYTa+qKu5TL9tvwtz0NnxGjEjOaQziDhtXgrMIzeBCyrIWBAuDrwG+3IVmfmA66L7PzWdUaouw0pMF2GiiBcsax2cSw8us6CCuZmXfe712omcZoAm3aKiZ4+d+NmM0aL0CWhuiVqmcg68LirMlzwNa+XJCJE9PZVjQrq66CIKAgad2BYFDMvQ66DuksiO94uePbRXqTTzM88dI6oIAOHL1YDp67orw0V+vdntZcq1V2fIJQyxuq87XnoN+dEFr/u+6HpRLYef9ihRn9iOGSm6l0z2X+fXT0nX1+UOLmg+UXTJ2BHL5VFCFCyJFAiJ8pNc8Hpx4QGlL50UXvA59wcEAoFAIBAIBAKBQCAQCAQCgUAgEAgEAoFAIBAIBAKBQCAQCARauVrEqsq8BYapl9hgQohbjU/lZ7d0WO01nxr1sXGfxNH+qG8QaBG4kEpLoUErL2L+sEvmmd6ihdXmZviI3Kfj/VHfINASRBwhNMULGhiwPCDb1m3WSOHk/qhvEGgBajwhLMULGxgwPLR6Lw94IREv4f6obxBoAVJU8LZh2olSfxAXvyBvPbQ7Zue8MAA0Ay+qycBLuD/qGwRaCC8k/IPGjhoauBhMjW1lt/OQl3B/1DcItBR/jIh2ihfWegYGd8tiYHmpxMBLtD/qGwRaULyPGudAESXhd4hNywZelLvFncPleGGt5yXaH/UNAi3CwFgaWBPG+9LKcJcLtiFJ1Vp3ixJrhjQlqhn1vET7o75BoGUAY60Ab2Ne3MfWumMqrtfuVkPDrJj6wYTdEu+P+gaBlkIM5cbzOuJFG49q4EW7WyYuaVyUT2w7shnvj/oGgZYjpD0vhQbCSo3hRW1QPhUjhhdiGnBDlOGlCUL8eH/UNwi0hHBfyrlWUX7MGAnLAjK8DAVIjYeNWpDfMNof9Q0CLUDW+Rrsi+NFxyUu6McmhA/q/8rhsiDYqJ5sxvujvkGghThiJskVxS8mjreLYmRIYkgiIQ9D1YV6gxLvj/oGgZYQ6/v5HeXHHC+Njf41L6b+qMS1yXC8mAKNbRzsj/oGgZYgV12J6y+yLG9gsMVHzUuQJ9aJ5qhKaY1RuD/qGwRahHRsMtT3HS/URB3ULBCjLui34Y3CSAyBPPeZ5XB/1DcItBC1GLf32DcIBAKBQCAQCAQCgUAgEAgEAoFAIBAIBAKBQCAQCAQCgUAgEGj5+j8eHEZblcGtHwAAAABJRU5ErkJggg==\" style=\"width:6.05208in;height:2.85694in\" alt=\"Resultado de imagem para gr√É¬°fico dos sinais e sintomas da doen√É¬ßa de kawasaki\" /></p>\n<ul>\n<li><p><strong>A DK √© dividida em 3 fases clinicas: aguda, subaguda e de\nconvalescen√ßa:</strong></p></li>\n</ul>\n<p><strong>Fase aguda:</strong></p>\n<p>Dura 1 a 2 semanas, compreende febre e os demais crit√©rios\ndiagn√≥sticos, al√©m de achados cl√≠nicos associados, como miocardite,\nderrame peric√°rdico, meningite ass√©ptica (10-25%), diarreia (15%),\ndisfun√ß√£o hep√°tica (5%), uve√≠te (17%) e artrite e/ou artralgia\n(30%).</p>\n<p><strong>Fase subaguda:</strong></p>\n<p>Inicia-se quando a febre, o rash e a linfadenopatia apresentam\nresolu√ß√£o, 1 a 2 semanas depois do in√≠cio da doen√ßa, por√©m h√°\nirritabilidade, anorexia e conjuntivite. Nessa fase, cuja dura√ß√£o √© de\ncerca de 4 semanas, ocorrem descama√ß√£o periungueal, trombocitose,</p>\n<p>forma√ß√£o de aneurismas coronarianos, e o risco de morte s√∫bita √©\nmaior. Complica√ß√µes neurol√≥gicas podem surgir em 1% dos casos e incluem\nparalisia de nervo facial, ataxia, encefalopatia, hemiplegia e infarto\ncerebral.</p>\n<p><strong>Fase de Convalescen√ßa:</strong></p>\n<p>Come√ßa quando os sinais cl√≠nicos desaparecem e vai at√© a normaliza√ß√£o\nda velocidade de hemossedimenta√ß√£o (VHS), durando, usualmente, de 6 a 8\nsemanas ap√≥s o in√≠cio do quadro febril.</p>\n<p><strong>Achados Clinicos Secund√°rios Da Doenca De\nKawasaki:</strong></p>\n<p><strong>Aparelho cardiovascular:</strong></p>\n<p>Miocardite, pericardite, regurgita√ß√£o valvular, aneurismas de\nart√©rias coron√°rias.</p>\n<p><strong>Aparelho musculoesquel√©tico:</strong></p>\n<p>Poliartrite e/ou artralgia;</p>\n<p>Rabdomi√≥lise.</p>\n<p><strong>Aparelho gastrointestinal:</strong></p>\n<p>Diarr√©ia, dor abdominal, v√¥mitos, disfun√ß√£o hep√°tica, pancreatite,\nves√≠cula hidr√≥pica, colangite, intussuscep√ß√£o, pseudo-obstru√ß√£o\nintestinal, ascite, infarto espl√™nico.</p>\n<p><strong>Aparelho Pulmonar:</strong></p>\n<p>Sintomas <em>influenza-like</em>, derrame pleural;</p>\n<p>Infiltrado pulmonar reticulogranular;</p>\n<p>Atelectasia.</p>\n<p><strong>Aparelho Geniturin√°rio:</strong></p>\n<p>Uretrite, prostatite, cistite, priapismo, insufici√™ncia renal aguda,\nnefrite intersticial, orquite, s√≠ndrome nefr√≥tica.</p>\n<p><strong>Sistema Nervoso Central:</strong></p>\n<p>Meningite ass√©ptica;</p>\n<p>Surdez neurossensorial.</p>\n<p><strong>Pele e Anexos:</strong></p>\n<p>Eritema e indura√ß√£o em s√≠tio de vacina√ß√£o de BCG;</p>\n<p>Linhas de Beau;</p>\n<p>Gangrena de dedos.</p>\n<ul>\n<li><p><strong>Exames Complementares Na Doen√ßa De\nKawasaki:</strong></p></li>\n</ul>\n<p>Leucocitose com neutrofilia e desvio para esquerda;</p>\n<p>Anemia normoc√≠tica e normocr√¥mica;</p>\n<p>Eleva√ß√£o da velocidade de hemossedimenta√ß√£o;</p>\n<p>Eleva√ß√£o da prote√≠na C reativa;</p>\n<p>Trombocitose (fase subaguda);</p>\n<p>Aumento moderado de transaminases;</p>\n<p>Hipoalbuminemia;</p>\n<p>Pi√∫ria est√©ril;</p>\n<p>L√≠quor com pleocitose com predom√≠nio de mononucleares;</p>\n<p>Hiponatremia;</p>\n<p>L√≠quido sinovial com leucocitose.</p>\n<ul>\n<li><p><strong>Ecocardiografia Bidimensional:</strong></p></li>\n</ul>\n<p>Por volta do 10¬∫ dia de doen√ßa pode demonstrar dilata√ß√µes\ncoronarianas e o pico de sua ocorr√™ncia se d√° com 4 semanas de\ndoen√ßa.</p>\n<ul>\n<li><p><strong>Solicitar no Pronto Socorro:</strong></p></li>\n</ul>\n<p>Hemograma, VHS(quando houver), hemocultura, transaminases, s√≥dio,\npot√°ssio, albumina s√©rica.</p>\n<p><strong>Avaliar necessidade:</strong></p>\n<p>urina tipo1, l√≠quor, RX de t√≥rax.</p>\n<p><strong>Assim que poss√≠vel:</strong> Ecocardiograma.</p>\n<ul>\n<li><p><strong>Diagn√≥stico Diferencial:</strong></p></li>\n</ul>\n<p>S√≠ndrome de Stevens Johnson;</p>\n<p>Farmacodermias;</p>\n<p>Exantemas virais febris (sarampo, adenov√≠rus, enterov√≠rus, v√≠rus\nEpstein-Barr);</p>\n<p>Artrite reumat√≥ide juvenil;</p>\n<p>S√≠ndrome da pele escaldada estafiloc√≥cica;</p>\n<p>S√≠ndrome do choque t√≥xico;</p>\n<p>Leptospirose;</p>\n<p>ntoxica√ß√£o por merc√∫rio;</p>\n<p>Sarampo;</p>\n<p>Escarlatina;</p>\n<p>Febre maculosa;</p>\n<p>Eritema perineal toxina mediado recorrente;</p>\n<p>Linfadenites cervicais bacterianas;</p>\n<ul>\n<li><p><strong>Tratamento:</strong></p></li>\n</ul>\n<p>Objetivo: reduzir a inflama√ß√£o e o dano arterial e prevenir a\ntrombose naqueles com anormalidades da art√©ria coron√°ria.</p>\n<p><strong>IVIG:</strong></p>\n<p>Deve ser institu√≠da nos primeiros 10 dias de in√≠cio da doen√ßa.</p>\n<p>Efeito anti-inflamat√≥rio generalizado;</p>\n<p>Dose alta: 2g/kg, em dose √∫nica, geralmente administrada durante 10 a\n12 horas, em BI;</p>\n<p>Mesmo quando tratados com regimes de IVIG em dose alta nos primeiros\n10 dias de doen√ßa:</p>\n<p>20% das crian√ßas desenvolver√£o dilata√ß√£o transit√≥ria da art√©ria\ncoron√°ria; ¬†</p>\n<p>5% desenvolver√£o aneurismas da art√©ria coron√°ria (¬†<em>Z</em>¬†&gt;\n2,5);</p>\n<p>1% desenvolver√° aneurismas gigantes;</p>\n<p>As imuniza√ß√µes contra o sarampo, a caxumba e a varicela devem ser\nadiadas por 11 meses ap√≥s o recebimento de IVIG em dose alta.</p>\n<p><strong>√Åcido acetilsalic√≠lico (AAS):</strong></p>\n<p>Importante atividade anti-inflamat√≥ria e antiagregante\nplaquet√°ria;</p>\n<p>N√£o diminui frequ√™ncia de anormalidades coronarianas;</p>\n<ul>\n<li><p><strong>Fase aguda:</strong></p></li>\n</ul>\n<p>80 a 100 mg/kg/dia;¬†</p>\n<p>O momento da redu√ß√£o da dose do AAS: 48 a 72 horas sem febre;</p>\n<p>AAS dose baixa (3 a 5 mg/kg/dia ): manter at√© que o paciente n√£o\ntenha evid√™ncias de altera√ß√µes coronarianas (6 a 8 semanas ap√≥s o in√≠cio\nda doen√ßa);¬†</p>\n<p>Anormalidades coronarianas: AAS cont√≠nuo;</p>\n<p><strong>ATEN√á√ÉO:</strong> O uso concomitante de ibuprofeno antagoniza\na antiagrega√ß√£o plaquet√°ria induzida pelo AAS ü°™ evitar seu uso em\ncrian√ßas com aneurismas da art√©ria coron√°ria.</p>\n<ul>\n<li><p><strong>Outras Terapias:</strong></p></li>\n</ul>\n<p><strong>Corticoester√≥ides:</strong></p>\n<p>Reduz a preval√™ncia de anormalidades da art√©ria coron√°ria, dura√ß√£o da\nfebre e inflama√ß√£o;</p>\n<p>Pode ser considerada para o tratamento de pacientes de alto risco com\nDAC aguda; ¬†</p>\n<p>Normalmente, metilprednisolona 20-30 mg / kg por via intravenosa\ndurante 3 dias, seguida ou n√£o da prednisona oral).</p>\n<p><strong>Imunobiol√≥gicos:</strong></p>\n<p><strong>Infliximabe</strong> (5 mg/kg): redu√ß√£o da resist√™ncia √† IVIG\nde 20% para 5%;</p>\n<p><strong>Etarnecepte</strong> (0,8 mg/kg);</p>\n<ul>\n<li><p><strong>Casos Resistentes ao Tratamento\nInicial:</strong></p></li>\n</ul>\n<p>10% a 20% dos pacientes com DK mant√©m febre 36 horas ap√≥s o t√©rmino\nda infus√£o de IVIG ü°™ resistentes √† IVIG</p>\n<p>Os pacientes que s√£o resistentes a IVIG inicial est√£o em maior risco\nde desenvolver anormalidades da art√©ria coron√°ria.</p>\n<ul>\n<li><p><strong>Tratamento:</strong></p></li>\n</ul>\n<p>Retratamento com IVIG 2g / kg;</p>\n<p>Corticoester√≥ides;</p>\n<p>Infliximabe;</p>\n<ul>\n<li><p><strong>Seguimento:</strong></p></li>\n</ul>\n<p>Todos os pacientes devem fazer seguimento ambulatorial com\nreumatologista pedi√°trico e, quando necess√°rio, com cardiopediatra\ntamb√©m.</p>\n<p>Pacientes sem comprometimento card√≠aco:</p>\n<p>Realizar o ecocardiograma ao diagn√≥stico, na 2¬™ semana e entre a 6¬™ e\n8¬™ semana.</p>\n<p>Pacientes com anormalidades da art√©ria coron√°ria importantes e em\nevolu√ß√£o (escores¬†<em>Z</em>¬†&gt; 2,5):</p>\n<p>Realizar ecocardiografia pelo menos 2x por semana at√© que pare de\nevoluir, 1x por semana nos primeiros 45 dias de doen√ßa e, em seguida,\nmensalmente at√© o 3¬∫ m√™s.</p>\n<ul>\n<li><p><strong>Evolu√ß√£o E Progn√≥stico:</strong></p></li>\n</ul>\n<p>A DK √© uma doen√ßa aguda e autolimitada. Ap√≥s a fase febril aguda,\ntodas as outras manifesta√ß√µes ir√£o regredir na fase subaguda ou na fase\nde convalescen√ßa, sem deixar sequelas, exceto as altera√ß√µes\ncardiovasculares. Cerca de 50% dos aneurismas regridem em 1 a 2 anos. A\nDK pode recorrer em 1,5 a 3% dos pacientes. O √≠ndice de letalidade no\nJap√£o caiu para 0,1%. Nos EUA, a mortalidade intra-hospitalar dos\npacientes com DK e de aproximadamente 0,17%. As mortes s√£o decorrentes\ndas sequelas card√≠acas. O pico de mortalidade ocorre entre 15 e 45 dias\nap√≥s o in√≠cio da febre; muitos casos, por√©m, aparecem tardiamente por\ninfarto agudo do mioc√°rdio secund√°rio √† trombose coronariana em √°reas de\naneurisma ou, mais raramente, por ruptura de aneurismas.</p>\n<ul>\n<li><p><strong>Refer√™ncias Bibliogr√°ficas:</strong></p></li>\n</ul>\n<p>1. Reumatologia para pediatras. Sheila Knupp de Oliveira. 2.ed ‚Äì Rio\nde Janeiro : Revinter, 2014.</p>\n<p>2. Castro PA, Urbano LMF, Costa. Doen√ßa de Kawasaki. IMCAn Bras\nDermatol. 2009;84(4):317-31.</p>\n<p>3. McCrindle, BW, et al; Diagnosis, Treatment, and Long-Term\nManagement of Kawasaki Disease. Circulation<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28356445\">.</a>¬†2017 Apr\n25.</p>\n<p>4. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Freeman%20AF%5bAuthor%5d&amp;cauthor=true&amp;cauthor_uid=17039750\">Freeman\nAF</a><sup>1</sup>,¬†<a href=\"https://www.ncbi.nlm.nih.gov/pubmed/?term=Shulman%20ST%5bAuthor%5d&amp;cauthor=true&amp;cauthor_uid=17039750\">Shulman\nST</a>. Kawasaki disease: summary of the American Heart Association\nguidelines. <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/17039750\">Am\nFam Physician.</a>¬†2006 Oct 1;74(7):1141-8.</p>\n<p>5. Castro, PA, et al. Doen√ßa de Kawasaki. An. Bras.\nDermatol.¬†vol.84¬†no.4¬†Rio de JaneiroJuly/Aug.¬†2009.</p>\n<p>Respons√°vel pela elabora√ß√£o da rotina: Dra. Dania Lemos Dion√≠zio</p>\n</body>\n</html>\n",
  "originalFilename": "DOEN√áA DE KAWASAKI ROTINAS HRT DANIA.html",
  "conversionMethod": "mammoth",
  "createdAt": "2025-10-23T00:12:51.033Z",
  "updatedAt": "2025-10-23T00:12:51.033Z"
}